Physician profile
Navkaranbir S Bajaj
NPI 1023321023
$512.77
in general payments reported to CMS, 2019-2025
11 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.15 · 2022: $50.33 · 2023: $47.25 · 2024: $93.33 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316 · Honoraria: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.29 |
| Honoraria | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $100.84 | 2025 | |
| Artrya Ltd. | $100.00 | 2025 | |
| Boston Scientific Corporation | $77.15 | 2021-2025 | Cds - Other |
| Amgen INC. | $73.74 | 2021-2025 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $34.40 | 2023-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $33.72 | 2022-2024 | Xarelto |
| Edwards Lifesciences Corporation | $33.62 | 2024 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $18.46 | 2024 | |
| Pfizer INC. | $17.69 | 2023 | |
| Medtronic, INC. | $15.80 | 2025 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.35 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navkaranbir Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.